ArticleDiagnostics (Basel, Switzerland)2022
Reinducing Radioiodine-Sensitivity in Radioiodine-Refractory Thyroid Cancer Using Lenvatinib (RESET): Study Protocol for a Single-Center, Open Label Phase II Trial.
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04858867 (Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Reinducing Radioiodine-sensitivity in Radioiodine-refractory Differentiated Thyroid Cancer Using Lenvatinib (RESET)
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- No reinduction of clinically relevant radioiodine uptake after lenvatinib treatment in radioidine-refractory differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Treatment with Kinase Inhibitors Plus Myo-Inositol as Re-Differentiating Agents in Iodine-Refractory Thyroid Cancers.Life (Basel, Switzerland) · 2026Article
- Thermal ablation for radioactive iodine refractory cervical lymph node metastasis in differentiated thyroid cancer.European radiology · 2026Article
- Application of Mendelian randomization and bioinformatic analysis to construct a prognostic model for thyroid cancer and perform pan-cancer analysis.Discover oncology · 2025Article
- Article
- Enhancing radioactive iodine (RAI) incorporation in RAI-refractory differentiated thyroid cancer: current insights.European thyroid journal · 2025Review
- Role of [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer.Current oncology (Toronto, Ont.) · 2024Review
- [Bioinformatic analysis of CCND2 expression in papillary thyroid carcinoma and its impact on immune infiltration].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.American journal of cancer research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.